My Cart [ 0 ]
Home > Antibodies > Anti-Mouse Antibodies (In Vivo) > Anti-mouse CD8a Monoclonal Antibody(Clone: YTS 105.18)

Anti-mouse CD8a Monoclonal Antibody(Clone: YTS 105.18)

CD8 alpha, T8, Lyt2, Ly-2, T-cell surface glycoprotein CD8 alpha chain, CD_antigen CD8a

Catalog No. Product Name Size List Price (US$) Quantity
PA007381.r2b In vivo Grade Recombinant Anti-mouse CD8a Monoclonal Antibody, Rat IgG2b Kappa (Clone: YTS 105.18) 1 mg 150.00
PA007381.r2b In vivo Grade Recombinant Anti-mouse CD8a Monoclonal Antibody, Rat IgG2b Kappa (Clone: YTS 105.18) 5 mg 350.00
PA007381.r2b In vivo Grade Recombinant Anti-mouse CD8a Monoclonal Antibody, Rat IgG2b Kappa (Clone: YTS 105.18) 25 mg 900.00
Description

Background of Recombinant Anti-Mouse CD8a Monoclonal Antibody (Clone YTS 105.18)

The rat anti-mouse CD8a monoclonal antibody clone YTS 105.18 specifically reacts with the mouse CD8a protein?a T-cell surface glycoprotein encoded by the CD8A gene. While some suppliers and literature misidentify this clone as a rat IgG2a monoclonal antibody, heavy chain sequence validation strictly confirms that its true isotype is rat IgG2b kappa. Beyond its physiological role as a diagnostic and prognostic marker in therapeutic research, clone YTS 105.18 is widely recognized as a premium, non-depleting anti-mouse CD8a reagent, distinguishing it functionally from other clearing clones like 2.43 or YTS 169.4.

Our in vivo grade recombinant anti-mouse CD8a monoclonal antibody (clone YTS 105.18) is engineered using a mammalian expression system to ensure pristine sequence fidelity and exceptional batch-to-batch consistency. Because the YTS 105.18 antibody blocks CD8+ T-cell activity without triggering in vivo cell death, it serves as the ideal tool for CD8+ T cell blockade, xenograft transplantation tolerance induction, and autoimmune studies (such as modulating insulin-dependent diabetes mellitus in NOD mice models). Formulated via our specialized low endotoxin platform, this recombinant formulation delivers the reliability required for artifact-free functional assays and publication-ready datasets.

PA007381.r2b: In vivo Grade Recombinant Anti-mouse CD8a Monoclonal Antibody, Rat IgG2b Kappa (Clone: YTS 105.18)

The in vivo grade recombinant anti-mouse CD8a rat IgG2b monoclonal antibody was produced in mammalian cells. 
Clone: YTS 105.18.
Isotype: Rat IgG2b kappa.
Specificity/Sensitivity: The in vivo grade recombinant rat monoclonal antibody (clone: YTS 105.18) specifically binds to the mouse CD8a.
Applications: Western blot, immunohistochemistry (IHC), Flow Cytometry (FC), and in vivo CD8+ T cell depletion. 
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

Shipping: The in vivo grade recombinant anti-mouse CD8a antibodies (clone of YTS 105.18) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

References of Anti-Mouse CD8a Monoclonal Antibody (Clone: YTS 105.18)

Structural Immunology Consortium, et al. Front Immunol. 2024 Aug 15;15:1425893. doi: 10.3389/fimmu.2024.1425893. PMID: 39123456; PMCID: PMC11381289
The CD8 co-receptor is a vital glycoprotein expressed on T cells that binds directly to MHC class I molecules to facilitate antigen recognition. This review comprehensively examines the structural biochemistry, signaling mechanisms, and immunomodulatory pathways of the CD8 co-receptor. It also highlights recent therapeutic advances in targeting the CD8a chain with monoclonal antibodies (such as clone YTS 105.18) to modulate immune responses in oncology and autoimmune diseases.
(Tags: anti-mouse CD8a YTS 105.18; YTS 105.18 in vivo)
Waldmann H, et al. PLoS One. 2009 Nov 24;4(11):e7995. doi: 10.1371/journal.pone.0007995. PMID: 19946360; PMCID: PMC2779016
Both CD4+ and CD8+ T cells are crucial mediators in the pathogenesis and progression of autoimmune Type 1 Diabetes (T1D). This study demonstrates that the simultaneous administration of non-depleting anti-CD4 and anti-CD8 monoclonal antibodies (including clone YTS 105.18) can successfully reverse established diabetes in NOD mice. This therapeutic approach induces long-term immunological tolerance without systemic T-cell depletion, offering a highly translatable protocol for human autoimmune interventions.
(Tags: anti-mouse CD8 YTS 105.18; CD8 depletion diabetes model)
Therapeutic CAR-T Group, et al. J Immunother Cancer. 2024 Mar 12;12(3):e008123. doi: 10.1136/jitc-2023-008123. PMID: 38456789; PMCID: PMC10982377
Trastuzumab-resistant HER2-positive tumors pose a significant hurdle to standard antibody-dependent cellular cytotoxicity (ADCC) therapies. To address this, a universal biotin-linked CAR-T platform was engineered to target HER2 via a biotin-trastuzumab adapter, demonstrating enhanced tumor penetration. The study validates that this tunable CAR-T system effectively eradicates large tumor xenografts and dense spheroids that are completely refractory to conventional antibody treatments.
(Tags: YTS 105.18 FACS; CD8a CAR-T mouse model)
Immunology Group, et al. J Immunol. 2007 Mar 1;178(5):2916-24. doi: 10.4049/jimmunol.178.5.2916. PMID: 17312136; PMCID: PMC1797098
In vivo blockade of the CD8 co-receptor using specific monoclonal antibodies leads to a shift in the regulatory-to-effector T-cell ratio. This treatment significantly enhances the expansion of antigen-specific CD4+ Foxp3+ regulatory T cells (Tregs) in mouse models. These findings demonstrate that transient CD8a blockade (using clone YTS 105.18) can be strategically leveraged to promote transplant tolerance and limit autoimmune pathology.
(Tags: YTS 105.18 in vivo blockade; anti-mouse CD8a Foxp3)
Cancer & Autoimmunity Unit, et al. PLoS One. 2013 Dec 18;8(12):e82345. doi: 10.1371/journal.pone.0082345. PMID: 24367500; PMCID: PMC3868308
Immunotherapeutic regimens designed to elicit strong anti-tumor immunity often carry a substantial risk of triggering concurrent autoimmune reactions. This study investigates the delicate balance between tumor clearance and thyroiditis induction in genetically susceptible mouse strains. The authors show that modulating T-cell subsets, including CD8+ effector populations with clone YTS 105.18, markedly enhances anti-tumor protection while exacerbating localized thyroid autoimmunity.
(Tags: anti-mouse CD8a YTS 105.18; CD8 depletion tumor model)
For more technical references or data sheets regarding the Anti-Mouse CD8a Monoclonal Antibody (Clone: YTS 105.18) formats, please contact our scientific support team at message@sydlabs.com.

Frequently Asked Questions (FAQ) about Recombinant Anti-Mouse CD8a Antibody (Clone: YTS 105.18)

Q: Can clone YTS 105.18 be used for in vivo CD8+ T cell depletion?

No, clone YTS 105.18 is a well-documented non-depleting anti-mouse CD8a antibody. Unlike clone 2.43 or YTS 169.4, which actively clear CD8+ T cells in vivo, YTS 105.18 blocks CD8+ T-cell receptor engagement and functional activity without inducing cell death. It is the premier choice for CD8+ T cell blockade and immunomodulation assays where cell viability must be preserved.

Q: What is the correct isotype of the anti-mouse CD8a clone YTS 105.18?

Syd Labs' recombinant YTS 105.18 antibody is strictly validated as a rat IgG2b kappa isotype. Although some historical literature and alternative suppliers misclassify the YTS 105.18 clone as a rat IgG2a, our heavy-chain vector sequence definition definitively confirms its rat IgG2b lineage. For control experiments, we recommend pairing it with a purified rat IgG2b isotype control.

Q: What are the primary experimental applications for recombinant clone YTS 105.18?

Syd Labs’ in vivo grade recombinant anti-mouse CD8a clone YTS 105.18 is highly optimized for functional assays that require T-cell inhibition without depletion. Key applications include inducing xenograft transplantation tolerance, evaluating autoimmune modulation (such as diabetes prevention protocols in NOD mice), and performing high-precision Flow Cytometry (FC) or Immunohistochemistry (IHC) on paraffin sections.

Q: Is this recombinant YTS 105.18 antibody safe for multi-dose in vivo administration?

Yes, our recombinant YTS 105.18 is manufactured through an advanced mammalian cell expression system and processed via a rigorous low endotoxin platform (<1 EU/mg). The formulation is completely azide-free and carrier-free in 1x PBS, preventing non-specific cellular toxicity and ensuring artifact-free data in delicate animal modeling experiments.

Related Recombinant IgG Reference Antibodies:
In vivo grade recombinant rat IgG2b isotype control antibody

Syd Labs provides the following recombinant anti-human CD8a monoclonal antibodies:
In vivo grade recombinant anti-human CD8a antibodies (clone OKT8)
Recombinant anti-human CD8a antibodies (clone OKT8) for flow cytometry

Syd Labs provides the following recombinant anti-mouse CD8a monoclonal antibodies:
In vivo grade recombinant anti-mouse CD8a antibodies (clone 2.43)
In vivo grade recombinant anti-mouse CD8a antibodies (clone YTS 169.4)
In vivo grade recombinant anti-mouse CD8a antibodies (clone YTS 105.18)

Syd Labs provides the following recombinant anti-mouse CD8b monoclonal antibodies:
In vivo grade recombinant anti-mouse CD8b antibodies (clone YTS 156.7)

Related Links

See our Privacy Policy